Zacks: Brokerages Anticipate Aadi Bioscience, Inc. (NASDAQ:AADI) to Announce -$0.72 EPS

Wall Street analysts expect that Aadi Bioscience, Inc. (NASDAQ:AADIGet Rating) will report ($0.72) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Three analysts have provided estimates for Aadi Bioscience’s earnings, with the lowest EPS estimate coming in at ($0.77) and the highest estimate coming in at ($0.66). Aadi Bioscience posted earnings per share of ($1.35) in the same quarter last year, which indicates a positive year over year growth rate of 46.7%. The company is expected to issue its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Aadi Bioscience will report full-year earnings of ($2.85) per share for the current year, with EPS estimates ranging from ($3.22) to ($2.26). For the next fiscal year, analysts anticipate that the company will post earnings of ($2.97) per share, with EPS estimates ranging from ($3.51) to ($2.30). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that cover Aadi Bioscience.

Aadi Bioscience (NASDAQ:AADIGet Rating) last posted its quarterly earnings data on Thursday, May 12th. The company reported ($0.66) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.02. During the same period in the previous year, the firm posted ($0.90) EPS.

A number of equities analysts have recently commented on the stock. Piper Sandler reduced their target price on shares of Aadi Bioscience from $50.00 to $30.00 in a research report on Thursday, May 12th. Zacks Investment Research cut Aadi Bioscience from a “buy” rating to a “hold” rating in a research note on Tuesday, January 25th. Finally, HC Wainwright dropped their price objective on Aadi Bioscience from $49.00 to $48.00 and set a “buy” rating on the stock in a research note on Monday, April 11th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from, the company presently has an average rating of “Buy” and a consensus target price of $40.20.

AADI traded up $0.49 during trading hours on Thursday, reaching $14.35. 71,306 shares of the company’s stock traded hands, compared to its average volume of 118,402. The firm has a market capitalization of $300.52 million, a PE ratio of -1.20 and a beta of 1.57. Aadi Bioscience has a 52-week low of $11.00 and a 52-week high of $49.80. The firm has a 50-day moving average price of $16.36 and a 200 day moving average price of $19.89.

In other Aadi Bioscience news, insider Neil Desai sold 3,550 shares of the stock in a transaction dated Friday, March 18th. The shares were sold at an average price of $20.07, for a total transaction of $71,248.50. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 7.10% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in AADI. VR Adviser LLC bought a new stake in shares of Aadi Bioscience in the 3rd quarter valued at about $44,919,000. BVF Inc. IL bought a new stake in shares of Aadi Bioscience in the 3rd quarter valued at about $33,689,000. Rock Springs Capital Management LP bought a new stake in shares of Aadi Bioscience in the 3rd quarter valued at about $22,459,000. RTW Investments LP bought a new stake in shares of Aadi Bioscience in the 3rd quarter valued at about $21,336,000. Finally, State Street Corp boosted its holdings in shares of Aadi Bioscience by 72.0% in the 1st quarter. State Street Corp now owns 535,578 shares of the company’s stock valued at $9,089,000 after buying an additional 224,178 shares in the last quarter. 62.56% of the stock is currently owned by institutional investors and hedge funds.

Aadi Bioscience Company Profile (Get Rating)

Aadi Bioscience, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, including tumor agnostic indications targeting specific genomic alterations that activate the mTOR pathway.

Read More

Get a free copy of the Zacks research report on Aadi Bioscience (AADI)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Aadi Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aadi Bioscience and related companies with's FREE daily email newsletter.